There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs that are highly effective,” Dr. Califf said. If doctors who read the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

Glucagon-like peptide-1 receptor agonists (also known as GLP-1s), including medications like Ozempic, Mounjaro and Zepbound ... and Wegovy, appeared to reduce the risk of Alzheimer’s disease ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Ozempic, Wegovy, Mounjaro, and Zepbound are all classified as GLP-1 ... and Alzheimer’s disease. Experts say the use of these medications is likely to grow in the future.